The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Melphalan flufenamide (melflufen) + novel agents for RRMM

During COMy 2020, Multiple Myeloma Hub Steering Committee Member Paul Richardson, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about advances in the novel, peptide-conjugated alkylator, melphalan flufenamide (melflufen).

Melphalan flufenamide (melflufen) + novel agents for RRMM

Melflufen has been successful in overcoming resistance to standard chemotherapeutics as well as novel agents, such as proteasome inhibitors and immunomodulatory drugs. The high lipophilicity of melflufen facilitates rapid entry into myeloma cells. Furthermore, its alkylating activity is initiated by aminopeptidases, which are often overexpressed by myeloma cells, making the agent particularly selective. As a result, melflufen is better tolerated, with fewer off-target effects than its predecessor, melphalan.

Here, Paul Richardson discusses the major findings from preclinical studies and topline data from ongoing clinical trials evaluating melflufen for the treatment of multiple myeloma.